Abstract
Background: Trastuzumab(T) plus lapatinib(L) has been demonstrated to significantly improve the outcome of HER2 positive heavily pretreated metastatic breast cancer (MBC) patients. Whether TL combined chemotherapy (TLC) can further improve the efficacy in HER2+ MBC remains to be further studied. The aim of this study was to assess real-world treatment patterns and clinical outcomes of patients treated with TLC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
